These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1627379)

  • 21. Prognostic factors in stage I ovarian carcinoma.
    Vergote I
    Verh K Acad Geneeskd Belg; 2001; 63(3):257-71; discussion 272-6. PubMed ID: 11499346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.
    Anttila MA; Kosma VM; Hongxiu J; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
    Br J Cancer; 1999 Apr; 79(11-12):1870-8. PubMed ID: 10206307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
    Berker B; Dunder I; Ensari A; Cengiz SD
    Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital.
    Unzelman RF
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 1):1663-71; discussion 1671-2. PubMed ID: 1615973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
    Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
    Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin chemotherapy of ovarian cancer: is short-term in vitro chemosensitivity predictive of long-term patient survival?
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    Aust N Z J Obstet Gynaecol; 1988 Nov; 28(4):313-7. PubMed ID: 3250450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.
    Frasci G; Conforti S; Zullo F; Mastrantonio P; Comella G; Comella P; Persico G; Iaffaioli RV
    Cancer; 1996 Mar; 77(6):1122-30. PubMed ID: 8635133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer?
    Thomas H; Nasim MM; Sarraf CE; Alison MR; Love S; Lambert HE; Price P
    Br J Cancer; 1995 Feb; 71(2):357-62. PubMed ID: 7841053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of cellular DNA content on survival in ovarian carcinoma.
    Klemi PJ; Joensuu H; Mäenpää J; Kiilholma P
    Obstet Gynecol; 1989 Aug; 74(2):200-4. PubMed ID: 2748056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
    Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
    Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
    van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
    J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of early course of breast carcinoma by thymidine labeling.
    Meyer JS; Friedman E; McCrate MM; Bauer WC
    Cancer; 1983 May; 51(10):1879-86. PubMed ID: 6831353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3H-thymidine labelling index (TLI) as a marker of tumour growth heterogeneity: evaluation in human solid carcinomas.
    Becciolini A; Balzi M; Barbarisi M; Faraoni P; Biggeri A; Potten CS
    Cell Prolif; 1997; 30(3-4):117-26. PubMed ID: 9375024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.